Cytarabine | Cytosine β-D-arabinofuranoside;Cytosine Arabinoside;U-19920A;NSC 287459;NSC 63878;1-β-D-Arabinofuranosylcytosine;Ara-C | 阿糖胞苷 | Antivirus | DNA/RNA Synthesis

首页 / / / / Cytarabine

阿糖胞苷 /Cytarabine 98%

货号：A568740 同义名： 阿糖胞苷 / Cytosine β-D-arabinofuranoside;Cytosine Arabinoside

Cytarabine是一种核苷类似物，诱导S期细胞周期停滞并抑制DNA聚合酶。它以16 nM的IC50抑制DNA合成，并对HSV具有抗病毒作用。阿糖胞苷还表现出抗正痘病毒的活性。

Cytarabine 化学结构
CAS号：147-94-4

Cytarabine 3D分子结构
CAS号：147-94-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Cytarabine 纯度/质量文件产品仅供科研

货号：A568740 标准纯度： 98% 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024, 67(17): 14974-14985. Ambeed. [ A288696 ]; • JMC, 2024, 67(17): 15061-15079. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

DNA 亚型比较

产品名称	DNA synthesis ↓ ↑	helicase ↓ ↑	RdRp ↓ ↑	ribonucleotide reductase ↓ ↑	tRNA synthetase ↓ ↑	YB-1 ↓ ↑	其他靶点	纯度
Fexinidazole	✔							98%
Daptomycin	✔							98%
Blasticidin S·HCl	✔							98%
Metronidazole	✔							98%
Daunorubicin HCl	+++ DNA synthesis, Ki: 20 nM							98%
Triglycidyl isocyanurate	✔						p53	98+%
Nedaplatin	✔							99%+
Bendamustine	✔							98+%
Trifluridine	✔							98%
Robinetin	✔							99%+
Carboplatin	✔							99%
Cidofovir	✔							99%
Cisplatin	✔							99%
Cytarabine	++++ DNA synthesis, IC50: 16 nM							98%
Acelarin	++++ DNA synthesis, EC50: 0.2 nM							99%+
Oxaliplatin	✔							98%
YK-4-279		✔						99%+
ML216		+ BLM^full-length, IC50: 2.98 μM BLM^636-1298, IC50: 0.97 μM						99%+
RK-33		✔						98%
Brr2-IN-3		✔						99%+
Phen-DC3 Trifluoromethanesulfonate		✔						98%
Favipiravir			✔					97%
Suramin sodium salt			++ RdRp, IC50: 0.26 μM					99%+
Clofarabine				++ Ribonucleotide reductase, IC50: 65 nM				97%
Didox				✔				98%
(E)-3-AP				✔				97%
Halofuginone					+++ prolyl-tRNA synthetase, Ki: 18.3nM			99%+
BC-LI-0186					+++ Leucyl-tRNA synthetase, IC50: 46.11 nM Leucyl-tRNA synthetase, Kd: 42.1 nM			98%
SU056						+ YB-1, IC50: 1.73 μM		98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Cytarabine 生物活性

靶点	DNA synthesis DNA synthesis, IC50:16 nM
描述	Cytarabine (Ara-C) is an antineoplastic and antileukemic agent in current clinical treatment. Cytarabine belongs to a class of nucleoside-analogue antimetabolite, which can enter into cells and be phosphorylated by deoxynucleoside salvage pathway and produce their activity by being incorporated into DNA during replication or repair, leading to inhibition of chain extension^[1]. Cytarabine, combined with other drugs, is mainly used in the treatment for acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) (see https://www.fda.gov/), also can be used in treatment for other cancer. Cytarabine can inhibit DNA synthesis mainly through being incorporated into cellular DNA by both repair and replication synthesis^[2]. Cytarabine can induce apoptosis, s phase arrest, as well as cell growth inhibition^[3]. Cytarabine is usually used in long-term neuron culture to reduce glial cells and enhance neurons for its mitotic inhibition^[4].
作用机制	Cytarabine, as nucleoside analogue, can inhibit DNA synthesis mainly through being incorporated into cellular DNA by both repair and replication synthesis.

Cytarabine 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
CCRF-CEM cell line		Function assay		Inhibit the replication of CCRF-CEM cell line in vitro, ED50=5 nM.	1995894
CCRF-CEM cell lines		Function assay	72 h	Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation, ED50=6 nM.	1652024
CCRF-CEM human leukemic lymphoblastoid cell lines		Cytotoxic assay		Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines, IC50=20 nM.	6827546
HeLa human cell lines		Function assay	144 h	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against HeLa human cell lines after 144 hr, ID50=0.1 μM	3625714

Cytarabine 动物研究

Dose

Mice: 50 mg/kg, 100 mg/kg^[5] (i.p.); 20 mg/kg, 60 mg/kg^[6] (s.c.)

Administration

i.p., s.c.

Pharmacokinetics

Animal	Nude mice^[7]	Dogs^[8]
Dose	2466 μmol/kg	25 mg/m2/h
Administration		s.c.
T_1/2	0.29 h
C_max		1.70 ± 0.66 μg/ml
AUC_0→∞	1553 nmol·h/mL
AUC		11.39 ± 3.37 h·μg/ml

Cytarabine 参考文献

[1]Johnson SA, et al. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother. 2001 Jun;2(6):929-43.

[2]Wills P, Hickey R, et al. A novel in vitro model system for studying the action of ara-C. Cancer Chemother Pharmacol. 1996;38(4):366-72.

[3]Wang X, Chen Z, et al. Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition. Haematologica. 2018 Mar;103(3):466-476.

[4]Schwieger J, Esser KH, et al. Establishment of a long-term spiral ganglion neuron culture with reduced glial cell number: Effects of AraC on cell composition and neurons. J Neurosci Methods. 2016 Aug 1;268:106-16.

[5]Zuber J, Radtke I, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009 Apr 1;23(7):877-89.

[6]Scatena CD, Kumer JL, et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8.

[7]Bayne WF, Mayer LD, et al. Pharmacokinetics of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci. 2009 Jul;98(7):2540-8.

[8]Early PJ, Crook KI, et al. Plasma and serum concentrations of cytarabine administered via continuous intravenous infusion to dogs with meningoencephalomyelitis of unknown etiology. J Vet Pharmacol Ther. 2017 Aug;40(4):411-414.

Cytarabine 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

4.11mL

0.82mL

0.41mL

20.56mL

4.11mL

2.06mL

41.12mL

8.22mL

4.11mL

Cytarabine 技术信息

CAS号	147-94-4
分子式	C₉H₁₃N₃O₅
分子量	243.21

别名	阿糖胞苷 ;Cytosine β-D-arabinofuranoside;Cytosine Arabinoside;U-19920A;NSC 287459;NSC 63878;1-β-D-Arabinofuranosylcytosine;Ara-C
运输	蓝冰

存储条件

粉末 Keep in dark place,Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 16 mg/mL(65.78 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H₂O: 45 mg/mL(185.02 mM)，配合低频超声助溶

动物实验配方

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

CCRF-CEM cell line	Function assay		Inhibit the replication of CCRF-CEM cell line in vitro, ED50=5 nM.	1995894
CCRF-CEM cell lines	Function assay	72 h	Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation, ED50=6 nM.	1652024
CCRF-CEM human leukemic lymphoblastoid cell lines	Cytotoxic assay		Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines, IC50=20 nM.	6827546
HeLa human cell lines	Function assay	144 h	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against HeLa human cell lines after 144 hr, ID50=0.1 μM	3625714
HL60 cells	Proliferation assay		In vitro inhibitory concentration against proliferation of HL60 cells, IC50=0.08 μM	12877593
human 2209-23 cells	Proliferation assay		Antiproliferative activity against human 2209-23 cells by [3H]thymidine incorporation scintillation proximity assay, IC50=0.029 μM	19055482
human 697 cell	Growth inhibition assay		Inhibition of human 697 cell growth in a cell viability assay, IC50=10.6 nM.	SANGER
human A427 cell	Growth inhibition assay		Inhibition of human A427 cell growth in a cell viability assay, IC50=34.49 nM.	SANGER
human A549 cell	Growth inhibition assay		Inhibition of human A549 cell growth in a cell viability assay, IC50=49.66 nM	SANGER
human BALL-1 cells	Growth inhibition assay	24 h	Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay, GI50=0.08 μM	22264170
human BB65-RCC cell	Growth inhibition assay		Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50=110.19 nM	SANGER
human BFTC-905 cell	Growth inhibition assay		Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=108.31 nM	SANGER
human BHT-101 cell	Growth inhibition assay		Inhibition of human BHT-101 cell growth in a cell viability assay, IC50=41.76 nM	SANGER
human CAKI-1 cell	Growth inhibition assay		Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay, GI50=0.12 μM	22264170
human CAKI-1 cell	Growth inhibition assay		Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50=120 nM	SANGER
human CCRF-CEM cells	Cytotoxic assay	3 days	Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay, IC50=1 nM.	19674903
human CCRF-CEM cells	Cytotoxic assay	48 h	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay, EC50=5.61 nM.	19743858
human CCRF-CEM cells	Cytotoxic assay	48 h	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50=6 nM.	22582991
human CCRF-CEM/C2 cells	Cytotoxic assay	48 h	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay, EC50=22.8 nM.	19743858
human CEM cells	Cytotoxic assay	48 h	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs, IC50=0.024 μM.	20000418
human CHP-212 cell	Growth inhibition assay		Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=33.47 nM.	SANGER
human COR-L105 cell	Growth inhibition assay		Inhibition of human COR-L105 cell growth in a cell viability assay, IC50=160.39 nM	SANGER
human CTB-1 cell	Growth inhibition assay		Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=34.3 nM	SANGER
human CTV-1 cell	Growth inhibition assay		Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=84.74 nM	SANGER
human ES1 cell	Growth inhibition assay		Inhibition of human ES1 cell growth in a cell viability assay, IC50=12.97 nM.	SANGER
human ES8 cell	Growth inhibition assay		Inhibition of human ES8 cell growth in a cell viability assay, IC50=123.93 nM	SANGER
human EW-1 cell	Growth inhibition assay		Inhibition of human EW-1 cell growth in a cell viability assay, IC50=138.62 nM	SANGER
human GP5d cell	Growth inhibition assay		Inhibition of human GP5d cell growth in a cell viability assay, IC50=102 nM	SANGER
human H460 cells	Function assay	24 h	Antitumor activity against human H460 cells after 24 hrs by MTT assay	20211564
human HCT116 cells	Function assay		Antitumor activity against human HCT116 cells after 24 hrs by MTT assay, IC50=0.1 μM	20211564
human HEL cell	Growth inhibition assay		Inhibition of human HEL cell growth in a cell viability assay, IC50=20.52 nM.	SANGER
human H-EMC-SS cell	Growth inhibition assay		Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50=145.28 nM	SANGER
human HL60 cells	Cytotoxic assay		Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay, IC50=0.049 μM.	22582991
human HL60 cells	Cytotoxic assay	48 h	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay, IC50=0.118 μM	19321234
human HMV-II cell	Growth inhibition assay		Inhibition of human HMV-II cell growth in a cell viability assay	SANGER
human HT-1080 cell	Growth inhibition assay		Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=114.47 nM	SANGER
human HT-29 cells	Proliferation assay		Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay, IC50=0.066 μM.	2778449
human J-RT3-T3-5 cell	Growth inhibition assay		Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50=68.42 nM	SANGER
human K5 cell	Growth inhibition assay		Inhibition of human K5 cell growth in a cell viability assay, IC50=43.2 nM	SANGER
human K562 cells	Cytotoxic assay		Cytotoxicity against human K562 cells by SRB assay, IC50=0.05 μM	24956556
human KE-37 cell	Growth inhibition assay		Inhibition of human KE-37 cell growth in a cell viability assay, IC50=110.85 nM	SANGER
human LB1047-RCC cell	Growth inhibition assay		Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=108.42 nM	SANGER
human LB2241-RCC cell	Growth inhibition assay		Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=55.34 nM	SANGER
human leukemia cell line(CCRF-CEM)	Cytotoxic assay		In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM), IC50=0.09 μM.	8917645
human MCF7 1K cells	Cytotoxic assay	3 days	Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay, IC50=40 nM.	19674903
human MCF7 cells	Cytotoxic assay	3 days	Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay, IC50=4 nM.	19674903
human MC-IXC cell	Growth inhibition assay		Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=41.41 nM.	SANGER
human MEL-JUSO cell	Growth inhibition assay		Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50=85.76 nM	SANGER
human MLMA cell	Growth inhibition assay		Inhibition of human MLMA cell growth in a cell viability assay, IC50=55.51 nM	SANGER
human MOLT-16 cell	Growth inhibition assay		Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=36.07 nM.	SANGER
human MOLT-4 cell	Growth inhibition assay		Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=89.67 nM	SANGER
human NB69 cell	Growth inhibition assay		Inhibition of human NB69 cell growth in a cell viability assay, IC50=79.48 nM	SANGER
human NCI-H1703 cell	Growth inhibition assay		Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50=49.81 nM	SANGER
human NCI-H292 cell	Growth inhibition assay		Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=114.2 nM	SANGER
human NCI-H510A cell	Growth inhibition assay		Inhibition of human NCI-H510A cell growth in a cell viability assay, IC50=68.26 nM	SANGER
human NCI-SNU-1 cell	Growth inhibition assay		Inhibition of human NCI-SNU-1 cell growth in a cell viability assay， IC50=96.77 nM	SANGER
human NEC8 cell	Growth inhibition assay		Inhibition of human NEC8 cell growth in a cell viability assay, IC50=134.21 nM	SANGER
human P12-ICHIKAWA cell	Growth inhibition assay		Inhibition of human P12-ICHIKAWA cell growth in a cell viability assay, IC50=5.54 nM.	SANGER
human P30-OHK cell	Growth inhibition assay		Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=56.5 nM	SANGER
human SAS cell	Growth inhibition assay		Inhibition of human SAS cell growth in a cell viability assay, IC50=107.57 nM	SANGER
human SF268 cells	Cytotoxic assay		Cytotoxicity against human SF268 cells by MTT assay, IC50=7.68 nM.	19345581
human SNU638 cells	Cytotoxic assay		Cytotoxicity against human SNU638 cells by SRB assay, IC50=0.15 μM	24956556
human SW982 cell	Growth inhibition assay		Inhibition of human SW982 cell growth in a cell viability assay, IC50=91.23 nM	SANGER
human T-24 cell	Growth inhibition assay		Inhibition of human T-24 cell growth in a cell viability assay, IC50=78.56 nM	SANGER
human VA-ES-BJ cell	Growth inhibition assay		Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50=71.65 nM	SANGER
L1210 cell lines	Function assay		Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation, ED50=0.05 μM.	1652024
L1210 murine cell lines	Function assay	72 h	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the L1210 murine cell lines after 72 hours, ID50=20 nM.	3625714
MOLT-4 human leukemic lymphoblastoid cell lines	Cytotoxic assay		Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines, IC50=10 nM.	6827546
mouse L1210 cells	Cytotoxic assay	3 days	Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay, IC50=0.4 nM.	19674903
mouse L1210 cells	Cytotoxic assay	48 h	Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs, IC50=0.024 μM.	20000418
murine leukemia P388	Function assay		Anticancer activity carried out in vitro against murine leukemia P388, IC50=0.14 μM	11356110
P388 murine cell lines	Function assay	72 h	The compound was tested in vitro for antitumor activity(50% inhibition of tumor cell growth) against the P388 murine cell lines after 72 hours, ID50=20 nM.	3625714
parent promyelocytic leukemia cell line	Function assay		Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+), ED50=47 nM.	3027329
RPMI-6410 human leukemic lymphoblastoid cell lines	Cytotoxic assay		Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines, IC50=0.06 μM	6827546

阿糖胞苷 /Cytarabine 98%

Cytarabine 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Cytarabine 质控信息

Cytarabine 生物活性

Cytarabine 细胞研究

Cytarabine 动物研究

Cytarabine 参考文献

Cytarabine 实验方案

Cytarabine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

阿糖胞苷 /Cytarabine 98%

Cytarabine 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Cytarabine 质控信息

Cytarabine 生物活性

Cytarabine 细胞研究

Cytarabine 动物研究

Cytarabine 参考文献

Cytarabine 实验方案

Cytarabine 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Cytarabine 纯度/质量文件产品仅供科研